In the BioHarmony Drug Report Database
Ombitasvir
Technivie, Viekirax (ombitasvir) is a small molecule pharmaceutical. Ombitasvir was first approved as Technivie on 2015-01-14. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Viekira pak’s patents are valid until 2032-04-13 (FDA).
Trade Name
|
Viekirax |
|---|---|
Common Name
|
ombitasvir |
ChEMBL ID
|
CHEMBL3127326 |
Indication
|
chronic hepatitis c, hepatitis c |
Drug Class
|
Antivirals: NS5A inhibitors |
Image (chem structure or protein)